Roche Ticlid Safety Program Is Promotional, Not Educational, Teva Asserts
Executive Summary
Roche's Ticlid (ticlopidine) educational program on the risks of neutropenia and agranulocytosis consists of promotional rather than safety information, Teva Pharmaceuticals maintains in a Jan. 6 letter to FDA.
You may also be interested in...
Torpharm Ticlopidine Ad To Run In August JAMA; Educational Materials Cited
Apotex' U.S. subsidiary Torpharm will run an advertisement in the August issue of the Journal of the American Medical Association referencing its safety education program for the first generic version of ticlopidine (Roche's Ticlid). Torpharm's ticlopidine cleared FDA July 1 with a therapeutically equivalent "AB" rating.
Torpharm Ticlopidine Ad To Run In August JAMA; Educational Materials Cited
Apotex' U.S. subsidiary Torpharm will run an advertisement in the August issue of the Journal of the American Medical Association referencing its safety education program for the first generic version of ticlopidine (Roche's Ticlid). Torpharm's ticlopidine cleared FDA July 1 with a therapeutically equivalent "AB" rating.
Roche "Revisiting" Safety Evaluation Post Posicor and Tasmar
Roche is "revisiting" its safety evaluation processes for new drugs following the worldwide withdrawal of Posicor (mibefradil) and the European suspension of Tasmar (tolcapone) in the second half of 1998, Roche CEO Franz Humer said during the firm's annual financial results meeting in Basel, Switzerland on March 30.